HealthJun 03, 2026

Apogee Therapeutics, Inc. raises $1.30B (Jun 2026)

$1.30B
$1.3B
Generated social card
Apogee Therapeutics, Inc. social card
Headline

APGE: Strong phase II-B results and a $1.3B Blackstone deal drive late-stage and combo program expansion - TradingView

About

Apogee Therapeutics, Inc. is focused on developing innovative therapies for atopic dermatitis and other conditions. The company is expanding its clinical trials into asthma and eosinophilic esophagitis (EoE), supported by a significant funding deal with Blackstone.

Article summary

APGE: Strong phase II-B results and a $1.3B Blackstone deal drive late-stage and combo program expansion  TradingView

Investors · 1
BlackstoneLead
FUND
Related rounds
Jul 11, 2026TJM Labs$100.0MSeries BUnited States
Jul 11, 2026Cent$5.0M——
Jul 10, 2026Upside$20.0MSeries AUnited States
Jul 10, 2026MindRank$52.0MSeries B—